Taaleri Bioteollisuus

Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a company producing cellulose-based materials with a high processing value

Share

TAALERI BIOINDUSTRY       PRESS RELEASE        30 MARCH 2023 AT 9:15 (EEST)


Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a company producing cellulose-based materials with a high processing value


Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a Finnish company producing cellulose-based materials with a high processing value. The purpose of the investment is to strengthen Nordic Bioproducts Groups’s (NBG) growth and expansion.

Nordic Bioproducts Group was founded in 2019 to develop new biomaterials based on the patented AaltoCell technology. The cellulose hybrids developed and manufactured by NBG are processed from Finnish forest fibres and cellulose-containing industrial and agricultural side and waste streams. The company aims to bring to the market environmentally more sustainable and low-emissions alternatives to fossil raw materials and harmful chemicals. For example, in the textile industry, pulp-based fibres can replace cotton and artificial fibres, and in the packaging industry, plastic. In the construction industry, bio-based pulp can be used, for example, in insulation and paints.

The investment is Taaleri Bioindustry Fund I’s third investment. The fund invests in industrial-scale production facilities and companies that can accelerate the scaling of bioindustry production. Products can be, for example, bio- and recycled fibres, organic fertilizers, functional biomaterials, and recycled materials to replace virgin products.

Taaleri Bioindustry Fund I complies with Article 9 of the EU Sustainable Finance Disclosure Regulation and is as such a so called dark green fund that only makes sustainable investments in projects that, for example, contribute substantially to climate change mitigation. The fund has raised over EUR 100 million and continues fundraising. The state-owned special-assignment companyFinnish Climate Fund is the fund’s anchor investor.

“We are very happy to start cooperation with Nordic Bioproducts Group. We believe that the company's innovative products have an international, growing market and the opportunity to expand operations to new fields as well”, says Tero Saarno, Director of Taaleri Bioindustry.

“We are very grateful and happy to have Taaleri Bioindustry Fund I as an investor and Taaleri’s bioindustry team as our partner. Among Finnish private equity investors, the team has unique know-how and understanding of the scaling of innovative bio- and circular economy projects. With the investment, we can ensure the construction of our production plant in Lappeenranta on time and at full scale”, says Olli Kähkönen, Director at NBG.

Taaleri’s vision is to be a Nordic pioneer in alternative investments focusing on sustainability. Through our private equity funds, we create, for example, wind andsolar power, bio-based products that replace fossil resources, andaffordable and energy-efficient rental homes.


For further information, please contact:
Tero Saarno, Director, Taaleri Bioindustry, +358 50 373 1923, tero.saarno@taaleri.com
Olli Kähkönen, Director, Nordic Bioproducts Group, +358 50 511 3970, olli.kahkonen@nordicbioproducts.fi

Taaleri in brief

Taaleri is a Nordic investment and asset manager with an emphasis on renewable energy and other alternative investments. We channel capital towards economically profitable undertakings that have a lasting positive impact on the environment and society. We combine capital with talent, expertise, entrepreneurship, and a bold sense of purpose. We are a signatory of the UN Principles for Responsible Investment (UNPRI) since 2010, and we joined the Net Zero Asset Managers initiative in 2021. Taaleri’s vision is to be a Nordic forerunner in alternative investments focusing on sustainability.

Taaleri has two business segments: Private Asset Management and Strategic Investments. Private Asset Management consists of renewable energy, real estate and bioindustry businesses. The Strategic Investments segment includes Garantia Insurance Company Ltd.

Taaleri has EUR 2.5 bn of assets under management in its private equity funds and co-investments. The company has approximately 120 employees. Taaleri Plc is listed on Nasdaq Helsinki.

www.taaleri.com


Nordic Bioproducts Group
in brief

Nordic Bioproducts Group (NBG) is an Aalto University spin-off and start up established in 2019 developing and commercializing intelligent bioproducts, biosystemsand circular innovations that minimise the environmental and social costs of large-scale production. The company’s ground-breaking Aaltocell™ technology allows it to produce high-value-adding Micro Crystalline Cellulose (E460, MCC) and biocomponents for a wide range of applications.

Working with e.g. food, cosmetics,pharma, plastics and textile industries, NBG wants to create a healthy carbon neutral everyday life for the people, sustainable future for the planet and profit for businesses.

www.nordicbioproducts.fi

About Taaleri Bioteollisuus

Taaleri Bioteollisuus
Kasarmikatu 21 B
00130 Helsinki

https://www.taaleribioteollisuus.com/

Subscribe to releases from Taaleri Bioteollisuus

Subscribe to all the latest releases from Taaleri Bioteollisuus by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Taaleri Bioteollisuus

Taalerin bioteollisuusrahasto sijoittaa sieniproteiinia valmistavaan Eniferiin23.5.2024 08:45:00 EEST | Tiedote

TAALERI BIOTEOLLISUUS LEHDISTÖTIEDOTE 23.5.2024 KLO 8.45 Taalerin bioteollisuusrahasto sijoittaa sieniproteiinia valmistavaan Eniferiin Taalerin bioteollisuuteen keskittyvä Bioteollisuus I -rahasto sijoittaa suomalaiseen sieni- eli mykoproteiinia valmistavaan Eniferiin. Sijoitus mahdollistaa uuden tuotantolaitoksen rakentamisen Kantvikiin Kirkkonummelle. Enifer perustettiin vuonna 2020 patentoidun PEKILO®-teknologian jatkokehittämistä ja kaupallistamista varten. Mykoproteiinin valmistuksessa hyödynnetään fermentointiprosessia, joka kehitettiin Suomessa alun perin 1970-luvulla. Nykyinen valmistustapa muistuttaa oluen tai soijan fermentointiprosessia. Eniferin mykoproteiini on kestävä vaihtoehto eläin- ja kasviproteiineille. Vaihtoehtoinen proteiininlähde edesauttaa biodiversiteetin säilymistä, sillä tuotanto ei vaadi maankäyttöä ja lisää sitä epäsuorasti vain vähän. Enifernin mykoproteiinilla on matala hiili- ja vesijalanjälki verrattuna eläin- ja kasviproteiineihin. PEKILO®-mykoproteii

Taaleri’s bioindustry fund invests in Enifer, a company producing mycoprotein23.5.2024 08:45:00 EEST | Press release

TAALERI BIOINDUSTRY PRESS RELEASE 23 MAY 2024 AT 8:45 (EEST) Taaleri’s bioindustry fund invests in Enifer, a company producing mycoprotein Taaleri Bioindustry Fund I invests in Enifer, a Finnish company producing fungi-based mycoprotein. Investment enables Enifer to construct a new mycoprotein factory in Kantvik, Kirkkonummi, Finland. Enifer was founded in 2020 to develop and commercialize the proprietary PEKILO® technology further. Mycoprotein is produced by cultivating a specific species of fungus in a fermentation process that is not too distinct from brewing beer or making soy sauce. The PEKILO® fermentation process was originally developed in Finland in the 1970s and used by the forest industry. Mycoprotein is a sustainable alternative to animal and some soy proteins. This alternative protein has a significant positive contribution to biodiversity because the production process does not require direct land use as many other plant and animal proteins do. The production of mycoprote

Taalerin bioteollisuusrahasto sijoittaa korkean jalostusarvon selluloosapohjaisia materiaaleja valmistavaan Nordic Bioproducts Groupiin30.3.2023 09:15:00 EEST | Tiedote

TAALERI BIOTEOLLISUUS LEHDISTÖTIEDOTE 30.3.2023 klo 9.15 Taalerin bioteollisuusrahasto sijoittaa korkean jalostusarvon selluloosapohjaisia materiaaleja valmistavaan Nordic Bioproducts Groupiin Taalerin bioteollisuuteen keskittyvä rahasto Taaleri Bioteollisuus I sijoittaa suomalaiseen korkean jalostusarvon selluloosapohjaisia materiaaleja valmistavaan Nordic Bioproducts Groupiin. Sijoituksella on tarkoitus vahvistaa Nordic Bioproducts Groupin (NBG) kasvua ja laajentumista. Nordic Bioproducts Group perustettiin vuonna 2019 kehittämään uusia biomateriaaleja, jotka perustuvat patentoituun AaltoCell-teknologiaan. NBG:n kehittämät ja valmistamat selluloosahybridit on jalostettu kotimaisista metsäkuiduista sekä selluloosaa sisältävistä teollisuuden ja maatalouden sivu- ja jätevirroista. Yhtiö pyrkii tuomaan markkinoille ympäristön kannalta kestävämpiä ja vähäpäästöisempiä vaihtoehtoja fossiilisille raaka-aineille ja haitallisille kemikaaleille. Esimerkiksi tekstiiliteollisuudessa sellupohjais

Taaleri’s first bioindustry fund invests in Nordtreat, a company producing bio-based flame retardants22.11.2022 09:15:00 EET | Press release

TAALERI BIOINDUSTRY PRESS RELEASE 22 NOVEMBER 2022 AT 9:15 (EET) Taaleri’s first bioindustry fund invests in Nordtreat, a company producing bio-based flame retardants Taaleri’s first bioindustry fund invests in Nordtreat, a Finnish company producing bio-based, environmentally friendly and non-harmful flame-retardants. The purpose of the investment is to strengthen Nordtreat's growth and expansion. Founded in 2015, Nordtreat manufactures bio-based flame-retardant chemicals for building materials made from renewable raw materials. The company has developed and commercialized fire retardants, especially for wood construction. The products are based on the company's patented fire protection technology. Nordtreat's products replace traditional flame-retardants that contain compounds that are harmful to humans and the environment, such as boric acid, formaldehyde, and ammonia. The investment is Taaleri Bioindustry I Fund’s second investment. The fund invests in industrial-scale production fa

Taalerin ensimmäinen bioteollisuusrahasto sijoittaa biopohjaisia palosuoja-aineita valmistavaan Nordtreat-yhtiöön22.11.2022 09:15:00 EET | Tiedote

TAALERI BIOTEOLLISUUS LEHDISTÖTIEDOTE 22.11.2022 klo 9.15 Taalerin ensimmäinen bioteollisuusrahasto sijoittaa biopohjaisia palosuoja-aineita valmistavaan Nordtreat-yhtiöön Taalerin ensimmäinen bioteollisuuteen keskittyvä rahasto Taaleri Bioteollisuus I sijoittaa suomalaiseen biopohjaisia, ympäristöystävällisiä palosuoja-aineita valmistavaan Nordtreat-yhtiöön. Sijoituksella on tarkoitus vahvistaa Nordtreatin kasvua ja laajentumista. Vuonna 2015 perustettu Nordtreat valmistaa biopohjaisia palosuojakemikaaleja uusiutuvista raaka-aineista valmistettaviin rakennusmateriaaleihin. Yhtiö on kehittänyt ja kaupallistanut palosuoja-aineita erityisesti puurakentamiseen. Tuotteet perustuvat yhtiön kehittämään patentoituun palosuojausteknologiaan. Nordtreatin tuotteet korvaavat perinteisiä palosuoja-aineita, jotka sisältävät ihmisille ja ympäristölle haitallisia yhdisteitä kuten boorihappoa, formaldehydia ja ammoniakkia. Sijoitus Nordtreatiin on Taaleri Bioteollisuus I -rahaston toinen sijoitus. Rah

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye